Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Malignant Melanoma

Free Subscription 04.03.2019 1 Am J Dermatopathol 1 Am J Surg 1 Ann Surg Oncol 1 Br J Cancer 1 Br J Dermatol 1 Cancer Res 1 Int J Cancer 1 J Am Acad Dermatol 2 J Clin Oncol 1 J Immunol 1 J Invest Dermatol 2 Melanoma Res 1 N Engl J Med 1 Nat Med 2 Oncogene 1 Oncol Rep 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Dermatopathol

1. AUNG PP, Nagarajan P, Tetzlaff MT, Curry JL, et al
   Melanoma With Loss of BAP1 Expression in Patients With No Family History of BAP1-Associated Cancer Susceptibility Syndrome: A Case Series.
   Am J Dermatopathol. 2019;41:167-179.
   PubMed     Text format     Abstract available
   
   

   
   Am J Surg

2. LUONG J, Milanese E, Fortino J, Vetto JT, et al
   Reduction of lymphocele rate in patients undergoing sentinel node biopsy for melanoma by intraoperative placement of plant-based hemostatic powder: Results of a prospective trial.
   Am J Surg. 2019 Feb 14. pii: S0002-9610(18)31490.
   PubMed     Text format     Abstract available
   
   

   
   Ann Surg Oncol

3. LEONG SP, Wu M, Lu Y, Torre DM, et al
   Correction to: Intraoperative Imaging with a Portable Gamma Camera May Reduce the False-Negative Rate for Melanoma Sentinel Lymph Node Surgery.
   Ann Surg Oncol. 2019 Feb 25. pii: 10.1245/s10434-019-07233.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

4. DONLEY GM, Liu WT, Pfeiffer RM, McDonald EC, et al
   Reproductive factors, exogenous hormone use and incidence of melanoma among women in the United States.
   Br J Cancer. 2019 Feb 28. pii: 10.1038/s41416-019-0411.
   PubMed     Text format     Abstract available
   
   

   
   Br J Dermatol

5. DUFFY DL, Lee KJ, Jagirdar K, Pflugfelder A, et al
   High naevus count and MC1R red hair alleles contribute synergistically to increased melanoma risk.
   Br J Dermatol. 2019 Mar 1. doi: 10.1111/bjd.17833.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Res

6. HAYES TK, Luo F, Cohen O, Goodale AB, et al
   A functional landscape of resistance to MEK1/2 and CDK4/6 inhibition in NRAS mutant melanoma.
   Cancer Res. 2019 Feb 28. pii: 0008-5472.CAN-18-2711.
   PubMed     Text format     Abstract available
   
   

   
   Int J Cancer

7. VERVER D, van der Veldt A, van Akkooi A, Verhoef C, et al
   Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: a Dutch population-based study.
   Int J Cancer. 2019 Feb 23. doi: 10.1002/ijc.32229.
   PubMed     Text format     Abstract available
   
   

   
   J Am Acad Dermatol

8. CAZZANIGA S, Castelli E, Di Landro A, Di Mercurio M, et al
   Mobile Teledermatology for Melanoma Detection. Assessment of Validity in the Framework of a Population-based Skin Cancer Awareness Campaign in Northern Italy.
   J Am Acad Dermatol. 2019 Feb 21. pii: S0190-9622(19)30327.
   PubMed     Text format    
   
   

   
   J Clin Oncol

9. LEBBE C, Meyer N, Mortier L, Marquez-Rodas I, et al
   Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
   J Clin Oncol. 2019 Feb 27:JCO1801998. doi: 10.1200/JCO.18.01998.
   PubMed     Text format     Abstract available
   
   
10. SHINDE A, Li R, Amini A, Glaser S, et al
    Can Immunotherapy Replace Radiotherapy in Melanoma Brain Metastases?
    J Clin Oncol. 2019 Feb 26:JCO1801982. doi: 10.1200/JCO.18.01982.
    PubMed     Text format    
    
    

    
    J Immunol

11. MITTAL P, Abblett R, Ryan JM, Hagymasi AT, et al
    An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.
    J Immunol. 2018;200:1513-1526.
    PubMed     Text format     Abstract available
    
    

    
    J Invest Dermatol

12. MCKEAN M, Oba J, Ma J, Roth KG, et al
    Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma.
    J Invest Dermatol. 2019;139:728-731.
    PubMed     Text format    
    
    

    
    Melanoma Res

13. STERA S, Balermpas P, Blanck O, Wolff R, et al
    Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma.
    Melanoma Res. 2019;29:187-195.
    PubMed     Text format     Abstract available
    
    
14. MAURER DM, Butterfield LH, Vujanovic L
    Melanoma vaccines: clinical status and immune endpoints.
    Melanoma Res. 2019;29:109-118.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

15. SAFA H, Glitza Oliva IC
    Cardiac Metastases in Melanoma.
    N Engl J Med. 2019;380:858.
    PubMed     Text format    
    
    

    
    Nat Med

16. HUANG AC, Orlowski RJ, Xu X, Mick R, et al
    A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
    Nat Med. 2019 Feb 25. pii: 10.1038/s41591-019-0357.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

17. STIEGLITZ D, Lamm S, Braig S, Feuerer L, et al
    BMP6-induced modulation of the tumor micro-milieu.
    Oncogene. 2019;38:609-621.
    PubMed     Text format     Abstract available
    
    
18. DANKNER M, Rose AAN, Rajkumar S, Siegel PM, et al
    Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Oncogene. 2018;37:3183-3199.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

19. PAN Z, Qu C, Chen Y, Chen X, et al
    Bufotalin induces cell cycle arrest and cell apoptosis in human malignant melanoma A375 cells.
    Oncol Rep. 2019 Feb 26. doi: 10.3892/or.2019.7032.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

20. GILMORE SJ
    Automated decision support in melanocytic lesion management.
    PLoS One. 2018;13:e0203459.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: